The abstract is read at the publisher; the summary is JClub's.
NXP800 suppresses HSF1 in glioblastoma by first reducing HSF1 transcriptional activity in a GCN2-independent manner, then later decreasing HSF1 translation via GCN2–p-eIF2 signaling.
- Why it matters: HSF1 and GCN2 both help cancer cells manage proteotoxic and amino-acid stress, but how NXP800 coordinates these pathways to shape glioblastoma outcomes was unclear.
- What they did: The authors treated glioblastoma models with NXP800 and tracked HSF1 transcriptional activity, HSF1 translation, and GCN2-dependent eIF2 phosphorylation over time, alongside AKT1 phosphorylation changes.
- The result: HSF1 suppression was linked to NXP800’s anti-proliferative effects, and patient/cell-line analyses showed a negative correlation between GCN2 and HSF1 signaling across multiple cancer types including glioblastoma.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.